George Dranitsaris
University of Ioannina
96 Papers
556 Citations
George Dranitsaris is an academic researcher from University of Ioannina. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 27, co-authored 82 publications. Previous affiliations of George Dranitsaris include University of Miami.
Chat about Author
Papers
A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes.
TL;DR: In this exploratory analysis, low levels of national preparedness, scale of testing and population characteristics were associated with increased national case load and overall mortality.
454
CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
Leonidas Benetatos,Eleftheria Hatzimichael,Aggeliki Dasoula,George Dranitsaris,Stavroula Tsiara,Maria Syrrou,Ioannis Georgiou,Konstantinos L. Bourantas +7 more
TL;DR: The findings suggest that these genes are abnormally methylated in AML and MDS patients, and methylation of MEG3 confers worse overall prognosis, and may serve as a useful biomarker in leukemia.
158
Biosimilars of Biological Drug Therapies Regulatory, Clinical and Commercial Considerations
TL;DR: The clinical, safety and submission requirements for biosimilars in several major markets are reviewed, issues of ongoing debate amongst key stakeholders are highlighted and some of the commercial challenges faced by developers of biosimilar are examined.
117
•Journal Article
Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.
Christopher M. Booth,Mark Clemons,George Dranitsaris,Anil A. Joy,Scott Young,Walter Callaghan,Maureen E. Trudeau,Teresa M. Petrella +7 more
TL;DR: The prevalence of severe CINV for breast cancer was relatively low compared with the prevalence reported in the literature, and several patient characteristics that predict which patients are at increased risk of developing severe symptoms were identified.
111
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
TL;DR: Patients with either progressive bone metastases or SREs while on clodronate or pamidronate may experience significant pain palliation with a switch to a more potent bisphosphonate, if confirmed by randomized trials.
55